Pfizer Inc
$222.05B- Market cap
- $158.39B
- Debt
- +$64.80B
- Cash
- −$1.14B
Capital structure 71% equity / 29% debt · EV / Revenue 3.55x
Quick read
Fair value engine
Each company valued on the other's multiple, then compared with the market price.
PFE · price snapshotP/E 20.43x
$27.79Snapshot Sep 8, 2026, 4:00 PM ET
Implied fair value · at MRNA's multiple
—
Needs MRNA P/E.
MRNA · price snapshot
—Price unavailable
Implied fair value · at PFE's multiple
—
Needs Annual EPS is negative.
Metric by metric
Smart diff
Where each company leads, and how wide the gap is.
6 metrics shown
MetricPFEMRNADifference (PFE − MRNA)
Revenue growth (YoY)
Growth edge
-1.6%
-39.9%
PFE: higher Revenue growth (YoY) by 38.3 percentage points
Gross margin
Reported gross margin
74.3%
55.3%
PFE: higher Gross margin by 19.0 percentage points
EBITDA proxy margin
Operating income + D&A
N/M
-147.3%
Insufficient data
EV/Revenue
Lower is better
3.55x
N/M
Insufficient data
P/E
Not comparable
20.43x
N/M
Not comparable
Net debt / EBITDA proxy
Lower leverage
N/M
N/M
Insufficient data
Statements
Side-by-side financials
Annual statements in reported currencies, with calculations and source evidence.
Income statement · reported unitsPFEMRNADelta
RevenueEnded 2025-12-31Ended 2025-12-31+USD 60.64B
Gross profitEnded 2025-12-31Ended 2025-12-31+USD 45.44B
Operating incomeEnded 2025-12-31—
EBITDA proxyEnded 2025-12-31—
Net incomeEnded 2025-12-31Ended 2025-12-31+USD 10.59B
Diluted / combined EPS (reported share)Ended 2025-12-31Ended 2025-12-31Different share bases
Revenue growthEnded 2025-12-31Ended 2025-12-31+38.3 pp
Gross marginEnded 2025-12-31Ended 2025-12-31+19.0 pp
Operating marginEnded 2025-12-31—
EBITDA proxy marginEnded 2025-12-31—
Net marginEnded 2025-12-31Ended 2025-12-31+157.6 pp
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Historical trends
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
PFEMRNA
Price framework
Enterprise value
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Moderna, Inc.
Price framework
Intrinsic value (DCF)
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PFIZER INC · implied price per share
$16.23−41.6% vs $27.79
$92.73B equity value÷5.71B shares=$16.23
Bear
$12.82
Base
$16.23
Bull
$22.30
Cash-flow base$11B
Growth0.0%
Balance sheet health
Solvency
Inspect reported liquidity and leverage alongside historical financial-health checks.
Piotroski F-Score
Financial strength on a 0–9 scale.
4/ 9 · PFEModerate
2/ 9 · MRNAWeak
Altman Z-Score
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Relative positioning
Where the pair sits against the wider comparable set.
Keep comparing
More comparisons
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.